Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15625124 | 0.82 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL17635362 | 0.79 | CYP4F2 (0.43) | — | |
| SCHEMBL10819867 | 0.78 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL15468707 | 0.75 | TSHR (0.32) | — | |
| SCHEMBL3072338 | 0.72 | TDP1 (0.32) | TDP1 | |
| SCHEMBL3141601 | 0.71 | DGAT1 (0.79) | DGAT1TDP1 | |
| SCHEMBL5823532 | 0.69 | — | — | |
| SCHEMBL9107639 | 0.69 | DGAT1 (0.36) | DGAT1TDP1 | |
| SCHEMBL2514266 | 0.69 | TDP1 (0.35) | TDP1 | |
| SCHEMBL16647560 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2307434-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | DGAT1 926/4885TDP1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.